Celladon Will Become Rare Disease-Focused Eiger

Celladon Corp. will be acquired in a reverse merger with Eiger BioPharmaceuticals Inc., which means Celladon will not have to liquidate its assets to return cash to shareholders following discontinuation of development for the genetically-targeted enzyme replacement therapy Mydicar for heart failure.